These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 20176993)
1. The numbers are in: statins for the primary prevention of cardiovascular disease in women. Duvernoy CS; Blumenthal R Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993 [No Abstract] [Full Text] [Related]
2. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Ridker PM; Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996 [No Abstract] [Full Text] [Related]
4. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor]. Olsson AG Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435 [No Abstract] [Full Text] [Related]
5. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439 [No Abstract] [Full Text] [Related]
11. The JUPITER Trial: responding to the critics. Ridker PM; Glynn RJ Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837 [No Abstract] [Full Text] [Related]
12. The JUPITER trial: How will it change clinical practice? Watson KE Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321 [TBL] [Abstract][Full Text] [Related]
13. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
14. [JUPITER study, more reason to give statins as preventive measure - commentary]. Narkiewicz K Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067 [No Abstract] [Full Text] [Related]
15. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Stewart RA Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039 [TBL] [Abstract][Full Text] [Related]
16. The JUPITER trial: results, controversies, and implications for prevention. Ridker PM Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):279-85. PubMed ID: 20031849 [No Abstract] [Full Text] [Related]
17. Rosuvastatin in patients with elevated C-reactive protein. Jenny-Avital ER N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275 [No Abstract] [Full Text] [Related]
18. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Wells MT; Eisenberg T Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368 [No Abstract] [Full Text] [Related]
19. [Statins in primary prophylaxis of cardiovascular diseases]. Kobalava ZhD; Villeval'de SV Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392 [TBL] [Abstract][Full Text] [Related]
20. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Vos E; Rose CP; Biron P Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369 [No Abstract] [Full Text] [Related] [Next] [New Search]